Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

BBNX

Beta Bionics Inc

Nov 07 • 04:00PM ET

26.30

+1.26 5.03 %

Healthcare • Medical Devices • USA • NASD

Held by: VTI IWM VXF IWO IHI SCHA VTWO XHE ITOT IWN

Index	RUT	P/E	-	EPS (ttm)	-1.79	Insider Own	24.65%	Shs Outstand	43.99M	Perf Week	-3.38%
Market Cap	1.16B	Forward P/E	-	EPS next Y	-1.80	Insider Trans	-0.85%	Shs Float	33.17M	Perf Month	18.31%
Enterprise Value	936.85M	PEG	-	EPS next Q	-0.40	Inst Own	91.55%	Short Float	12.57%	Perf Quarter	83.92%
Income	-77.84M	P/S	13.07	EPS this Y	77.07%	Inst Trans	9.67%	Short Ratio	5.18	Perf Half Y	88.53%
Sales	88.57M	P/B	3.93	EPS next Y	8.87%	ROA	-36.46%	Short Interest	4.17M	Perf YTD	11.30%
Book/sh	6.70	P/C	5.06	EPS next 5Y	40.77%	ROE	-47.52%	52W High	30.47 -13.69%	Perf Year	-
Cash/sh	5.19	P/FCF	-	EPS past 3/5Y	8.56% -	ROIC	-25.91%	52W Low	8.89 195.84%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	1807.41% -	Gross Margin	54.51%	Volatility	7.61% 8.11%	Perf 5Y	-
Dividend TTM	-	EV/Sales	10.58	EPS Y/Y TTM	-39.19%	Oper. Margin	-77.45%	ATR (14)	1.92	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.83	Sales Y/Y TTM	67.01%	Profit Margin	-87.89%	RSI (14)	61.04	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	10.64	EPS Q/Q	-43.31%	SMA20	11.47%	Beta	-	Target Price	31.30
Payout	-	Debt/Eq	0.03	Sales Q/Q	63.14%	SMA50	15.96%	Rel Volume	0.77	Prev Close	25.04
Employees	291	LT Debt/Eq	0.02	Earnings	Oct 28 AMC	SMA200	50.30%	Avg Volume	805.29K	Price	26.30
IPO	Jan 30, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	21.99% 13.68%	Trades		Volume	616,346	Change	5.03%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Resumed	Stifel	Buy	$26
Oct-01-25	Upgrade	Goldman	Neutral → Buy	$26
Jun-16-25	Initiated	Truist	Buy	$26
Jun-12-25	Initiated	Lake Street	Buy	$30
May-30-25	Initiated	Wolfe Research	Outperform	$20
May-30-25	Initiated	Goldman	Neutral	$16
Feb-24-25	Initiated	Stifel	Buy	$25
Feb-24-25	Initiated	Piper Sandler	Overweight	$26
Feb-24-25	Initiated	Leerink Partners	Outperform	$28
Feb-24-25	Initiated	Lake Street	Buy	$30
Feb-24-25	Initiated	BofA Securities	Buy
Feb-20-25	Initiated	Robert W. Baird	Neutral	$20
Feb-20-25	Initiated	Ladenburg Thalmann	Neutral	$20

Show Previous Ratings

Nov-03-25 04:08PM	Beta Bionics Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-25 03:25PM	Beta Bionics Inc (BBNX) Q3 2025 Earnings Call Highlights: Record Growth and Strategic Challenges (GuruFocus.com)
Oct-28-25 06:30PM	Beta Bionics, Inc. (BBNX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +10.34%
04:02PM	Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance (GlobeNewswire)
Oct-27-25 09:38AM	What to Expect from Beta Bionics Inc (BBNX) Q3 2025 Earnings (GuruFocus.com) +13.37%
04:33PM	Loading…
Oct-16-25 04:33PM	Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook (Insider Monkey)
Oct-09-25 08:00AM	Beta Bionics to Announce Third Quarter 2025 Financial Results on October 28, 2025 (GlobeNewswire)
Aug-21-25 08:00AM	Beta Bionics Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +10.39%
Jul-30-25 03:17AM	Beta Bionics Inc (BBNX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... (GuruFocus.com) +14.32%
Jul-29-25 04:02PM	Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance (GlobeNewswire)
03:20PM	Medtech IPOs Spur Talk of Broader US Health-Care Listing Revival (Bloomberg)
Jul-04-25 02:43AM	Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas (Insider Monkey)
Jul-02-25 07:30AM	Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire)
Jun-24-25 03:59PM	Abvance Therapeutics Secures Strategic Seed Financing & Leadership Expansion at ADA Scientific Sessions (GlobeNewswire)
06:56AM	ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors (MedTech Dive)
11:20AM	Loading…
Jun-23-25 11:20AM	BBNX Stock May Gain From Abbott Deal to Advance iLet Integration (Zacks) -11.68%
Jun-20-25 07:06AM	5 things to watch at the ADAs Scientific Sessions (MedTech Dive)
Jun-19-25 07:00AM	Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott's Future Dual Glucose-Ketone Sensor (GlobeNewswire)
Jun-16-25 10:21AM	Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth (Investing.com)
Jun-02-25 05:01AM	Beta Bionics CEO, CFO on how to take a company public (MedTech Dive) +8.41%
May-29-25 05:44AM	The medtech IPO window is finally open. Or is it? (MedTech Dive) +6.44%
May-07-25 03:22AM	Beta Bionics Inc (BBNX) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... (GuruFocus.com) +26.61%
May-06-25 04:02PM	Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025 (GlobeNewswire)
May-01-25 08:00AM	Beta Bionics to Present at the Bank of America Securities Health Care Conference (GlobeNewswire)
Apr-24-25 11:44AM	Beta Bionics: Slowing Down Or Being Conservative? (Seeking Alpha) +5.74%
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-16-25 04:05PM	Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025 (GlobeNewswire)
Apr-09-25 07:30AM	Beta Bionics to Host Investor Event on June 22, 2025 (GlobeNewswire) +21.63%
Mar-28-25 06:00AM	Newly public Beta Bionics reports sales surge; Dexcom hires CCO (MedTech Dive) -7.58%
Mar-27-25 04:45PM	Beta Bionics Announces Board Appointment of Gerard Michel (GlobeNewswire)
04:02PM	Loading…
Mar-25-25 04:02PM	Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025 (GlobeNewswire) -13.60%
Mar-03-25 12:59PM	Beta Bionics, Inc. (BBNX): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-27-25 07:00AM	Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 (GlobeNewswire)
Feb-21-25 09:35AM	Palantir initiated, Roku upgraded: Wall Streets top analyst calls (TipRanks)
Jan-31-25 05:56PM	Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
06:34AM	Beta Bionics raises $204M in IPO (MedTech Dive)
Jan-30-25 12:55PM	Beta Bionics raises $204m to kickstart medtech IPO season (Medical Device Network)
Jan-29-25 10:34PM	Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering (GlobeNewswire)

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lezack Adam	Director	Oct 31 '25	Sale	26.87	1,406	37,780	9,841	Nov 05 09:45 PM
Palasis Maria	Director	Oct 31 '25	Sale	26.91	1,406	37,834	9,841	Nov 05 09:45 PM
ADAM LEZACK	Director	Oct 31 '25	Proposed Sale	26.78	2,812	75,305		Oct 31 04:14 PM
MARIA PALASIS	Director	Oct 31 '25	Proposed Sale	26.78	2,812	75,305		Oct 31 04:13 PM
Feider Stephen	Chief Financial Officer	Oct 03 '25	Option Exercise	5.10	4,982	25,408	49,023	Oct 07 04:15 PM
Feider Stephen	Chief Financial Officer	Oct 03 '25	Sale	21.69	4,982	108,076	44,041	Oct 07 04:15 PM
Feider Stephen	Chief Financial Officer	Oct 01 '25	Option Exercise	5.10	15,018	76,592	59,059	Oct 03 04:31 PM
Feider Stephen	Chief Financial Officer	Oct 01 '25	Sale	20.76	15,018	311,806	44,041	Oct 03 04:31 PM
Stephen Feider	Officer	Oct 03 '25	Proposed Sale	21.69	4,982	108,076		Oct 03 03:34 PM
Stephen Feider	Officer	Oct 01 '25	Proposed Sale	20.76	15,018	311,837		Oct 01 04:42 PM
Feider Stephen	Chief Financial Officer	Sep 08 '25	Option Exercise	5.10	9,900	50,490	53,941	Sep 09 04:12 PM
Feider Stephen	Chief Financial Officer	Sep 08 '25	Sale	21.13	9,900	209,151	44,041	Sep 09 04:12 PM
Hopman Mark	Chief Commercial Officer	Sep 05 '25	Option Exercise	5.10	11,411	58,196	42,626	Sep 08 06:15 PM
Hopman Mark	Chief Commercial Officer	Sep 04 '25	Option Exercise	5.10	4,749	24,220	38,033	Sep 08 06:15 PM
Hopman Mark	Chief Commercial Officer	Sep 05 '25	Sale	20.56	11,411	234,657	31,215	Sep 08 06:15 PM
Hopman Mark	Chief Commercial Officer	Sep 04 '25	Sale	19.97	6,818	136,180	31,215	Sep 08 06:15 PM
Feider Stephen	Chief Financial Officer	Sep 05 '25	Option Exercise	5.10	100	510	44,141	Sep 08 06:15 PM
Feider Stephen	Chief Financial Officer	Sep 05 '25	Sale	21.00	100	2,100	44,041	Sep 08 06:15 PM
Feider Stephen	Officer	Sep 08 '25	Proposed Sale	21.13	9,900	209,152		Sep 08 02:23 PM
Hopman Mark	Officer	Sep 05 '25	Proposed Sale	20.56	11,411	234,657		Sep 05 05:24 PM
Feider Stephen	Officer	Sep 05 '25	Proposed Sale	21.00	100	2,100		Sep 05 05:12 PM
Saint Sean	President & CEO	Sep 02 '25	Sale	18.86	3,359	63,361	101,202	Sep 04 06:45 PM
Russell Steven Jon	Chief Medical Officer	Sep 02 '25	Sale	18.86	1,015	19,146	71,017	Sep 04 06:45 PM
Mensinger Mike	Chief Product Officer	Sep 02 '25	Sale	18.86	1,089	20,542	91,815	Sep 04 06:45 PM
Hopman Mark	Chief Commercial Officer	Sep 02 '25	Sale	18.86	848	15,996	33,284	Sep 04 06:45 PM
Feider Stephen	Chief Financial Officer	Sep 02 '25	Sale	18.86	1,462	27,578	44,041	Sep 04 06:45 PM
Hopman Mark	Officer	Sep 04 '25	Proposed Sale	19.97	6,818	136,180		Sep 04 04:33 PM
Feider Stephen	Chief Financial Officer	Aug 22 '25	Option Exercise	5.10	4,413	22,506	49,916	Aug 26 04:29 PM
Feider Stephen	Chief Financial Officer	Aug 22 '25	Sale	17.01	4,413	75,083	45,503	Aug 26 04:29 PM
Feider Stephen	Officer	Aug 22 '25	Proposed Sale	17.01	4,413	75,083		Aug 22 11:10 AM
Hopman Mark	Chief Commercial Officer	Aug 19 '25	Option Exercise	5.10	16,158	82,406	50,290	Aug 20 09:30 PM
Hopman Mark	Chief Commercial Officer	Aug 19 '25	Sale	16.61	16,158	268,376	34,132	Aug 20 09:30 PM
Feider Stephen	Chief Financial Officer	Aug 19 '25	Option Exercise	5.10	5,587	28,494	51,090	Aug 20 09:30 PM
Feider Stephen	Chief Financial Officer	Aug 19 '25	Sale	17.03	5,587	95,172	45,503	Aug 20 09:30 PM
Feider Stephen	Officer	Aug 19 '25	Proposed Sale	17.03	5,587	95,172		Aug 19 05:41 PM
Hopman Mark	Officer	Aug 19 '25	Proposed Sale	16.61	16,158	268,376		Aug 19 05:30 PM
Sean Saint	Officer	Jun 02 '25	Proposed Sale	17.89	3,439	61,524		Jun 09 08:30 PM
Hopman Mark	Chief Commercial Officer	Jun 02 '25	Sale	17.89	868	15,529	34,132	Jun 04 07:30 PM
Russell Steven Jon	Chief Medical Officer	Jun 02 '25	Sale	17.89	1,039	18,588	72,032	Jun 04 07:30 PM
Mensinger Mike	Chief Product Officer	Jun 02 '25	Sale	17.89	1,115	19,948	92,904	Jun 04 07:30 PM
Feider Stephen	Chief Financial Officer	Jun 02 '25	Sale	17.89	1,497	26,783	45,503	Jun 04 07:30 PM
Saint Sean	President & CEO	Jun 02 '25	Sale	17.89	3,439	61,526	104,561	Jun 04 07:30 PM
Mensinger Mike	Chief Product Officer	Jan 31 '25	Buy	17.00	33,350	566,950	59,019	Feb 03 08:30 PM
Mensinger Mike	Chief Product Officer	Jan 31 '25	Sale	17.00	13	221	25,669	Feb 03 08:30 PM
Wellington Hadley Harbor Aggre	10% Owner	Jan 31 '25	Buy	17.00	1,000,000	17,000,000	3,901,599	Feb 03 04:49 PM

Open in Screener

LYRA

Lyra Therapeutics Inc

Nov 07 • 04:00PM ET

4.61

-0.29 -5.92 %

Healthcare • Biotechnology • USA • NASD

LYRA Lyra Therapeutics Inc daily Stock Chart

Peers: JNJ PFE MRK GSK BMY LLY REGN AMGN VRTX ALNY

| Held by: VTI VXF DFAS

Index	-	P/E	-	EPS (ttm)	-29.46	Insider Own	8.53%	Shs Outstand	1.63M	Perf Week	-19.97%
Market Cap	7.58M	Forward P/E	-	EPS next Y	-9.59	Insider Trans	-1.58%	Shs Float	1.50M	Perf Month	-42.16%
Enterprise Value	10.28M	PEG	-	EPS next Q	-5.25	Inst Own	30.05%	Short Float	2.53%	Perf Quarter	-30.88%
Income	-38.84M	P/S	9.85	EPS this Y	73.00%	Inst Trans	-9.19%	Short Ratio	1.36	Perf Half Y	-6.11%
Sales	0.77M	P/B	4.62	EPS next Y	50.31%	ROA	-52.78%	Short Interest	0.04M	Perf YTD	-55.33%
Book/sh	1.00	P/C	0.25	EPS next 5Y	54.56%	ROE	-238.26%	52W High	37.50 -87.71%	Perf Year	-65.53%
Cash/sh	18.10	P/FCF	-	EPS past 3/5Y	24.62% -2.22%	ROIC	-131.43%	52W Low	3.81 20.99%	Perf 3Y	-98.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	75.25% -	Gross Margin	32.73%	Volatility	10.14% 8.09%	Perf 5Y	-99.16%
Dividend TTM	-	EV/Sales	13.35	EPS Y/Y TTM	63.76%	Oper. Margin	-4647.79%	ATR (14)	0.53	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.78	Sales Y/Y TTM	-57.69%	Profit Margin	-5043.64%	RSI (14)	25.80	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.78	EPS Q/Q	85.00%	SMA20	-26.24%	Beta	-0.01	Target Price	11.50
Payout	-	Debt/Eq	20.05	Sales Q/Q	-69.40%	SMA50	-30.05%	Rel Volume	1.40	Prev Close	4.90
Employees	30	LT Debt/Eq	17.24	Earnings	Aug 12 AMC	SMA200	-42.02%	Avg Volume	27.94K	Price	4.61
IPO	May 01, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	0.30% -17.44%	Trades		Volume	39,101	Change	-5.92%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Downgrade	Jefferies	Buy → Hold	$10 → $0.50
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $2
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy	$15
Aug-31-23	Initiated	H.C. Wainwright	Buy	$12
May-24-22	Initiated	Cantor Fitzgerald	Overweight	$15
May-26-20	Initiated	William Blair	Outperform
May-26-20	Initiated	Jefferies	Buy	$24
May-26-20	Initiated	BTIG Research	Buy	$28
May-26-20	Initiated	BofA/Merrill	Buy	$21

Show Previous Ratings

Nov-06-25 09:15AM	Dentsply International (XRAY) Lags Q3 Earnings Estimates (Zacks) -12.81%
Nov-04-25 09:15AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.30%
Oct-06-25 07:00AM	Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study (GlobeNewswire) +15.57%
Aug-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.00%
04:01PM	Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
08:55AM	Loading…
Aug-08-25 08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jun-27-25 08:00AM	Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -31.91%
Jun-12-25 12:00PM	Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why (Zacks) -12.22%
Jun-05-25 12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks) +11.00%
Jun-02-25 12:08PM	Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win (GuruFocus.com) +310.75%
07:00AM	Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) (GlobeNewswire)
May-07-25 07:00AM	Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 (GlobeNewswire)
May-06-25 05:20PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-31-25 06:55PM	Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -9.07%
04:01PM	Loading…
Mar-13-25 04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-09-25 12:00PM	Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-12-24 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -28.11%
04:01PM	Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-15-24 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Sep-27-24 07:00AM	Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings (GlobeNewswire) +10.07%
Aug-14-24 09:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:30PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-15-24 11:35AM	Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1? (Insider Monkey)
May-21-24 10:31AM	Lyra Therapeutics Reduces Workforce to Extend Cash Runway (MT Newswires)
09:14AM	Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital (GlobeNewswire)
May-07-24 09:54AM	Target upgraded, CVS downgraded: Wall Street's top analyst calls (The Fly) -19.46%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:38AM	--HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy (MT Newswires)
12:08PM	Loading…
May-06-24 12:08PM	DJT Stock: Trump Media Fires Accounting Firm, Hires Replacement After SEC Charges (InvestorPlace) -87.06%
11:32AM	ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range? (InvestorPlace)
11:07AM	Warren Buffett Just Gave Up on Paramount (PARA) Stock (InvestorPlace)
10:51AM	Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today? (InvestorPlace)
08:52AM	Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell (MT Newswires)
07:59AM	Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Apr-30-24 09:56PM	LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) +9.09%
05:30PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:04PM	Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-24 04:51PM	Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.70%
Mar-28-24 07:08AM	Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock? (Zacks)
Mar-25-24 08:50AM	Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-23-24 05:31AM	Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections (GuruFocus.com)
Mar-22-24 09:55AM	Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High? (Zacks)
Mar-21-24 10:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-24 08:50AM	Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going (Zacks)
Mar-01-24 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.17%
Feb-26-24 03:58AM	Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength? (Zacks)
Feb-21-24 08:50AM	Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength (Zacks)
Jan-17-24 08:50AM	What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing' (Zacks)
Nov-07-23 04:01PM	Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 07:00AM	Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer (GlobeNewswire)
Sep-13-23 01:22PM	Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up (Zacks)
Sep-12-23 07:00AM	Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery (GlobeNewswire) +7.48%
Sep-06-23 08:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Aug-08-23 05:50PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:30AM	Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference (GlobeNewswire)
Jun-02-23 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
07:30AM	Lyra Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Lyra Therapeutics Announces Closing of $50.0 Million Private Placement (GlobeNewswire) +5.06%
May-26-23 07:57AM	Lyra Therapeutics Announces $50.0 Million Private Placement (GlobeNewswire) +6.58%
May-14-23 08:19AM	Lyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-12-23 08:15AM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:01PM	Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-29-23 08:19AM	Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) biggest owners are retail investors who got richer after stock soared 18% last week (Simply Wall St.)
Apr-25-23 07:59AM	Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Mar-29-23 04:06PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-20-23 01:11PM	Estimating The Intrinsic Value Of Lyra Therapeutics, Inc. (NASDAQ:LYRA) (Simply Wall St.)
Mar-01-23 05:21AM	Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks) -5.04%
Feb-28-23 05:17AM	Lyra Therapeutics, Inc. (NASDAQ:LYRA) insiders placed bullish bets worth US$1.5m in the last 12 months (Simply Wall St.)
Feb-27-23 07:59AM	Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer (GlobeNewswire)
Feb-07-23 01:23PM	Here's Why We're Watching Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Situation (Simply Wall St.)
Feb-06-23 07:56AM	Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients (GlobeNewswire)
Jan-17-23 06:42PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-20-22 08:52AM	Further weakness as Lyra Therapeutics (NASDAQ:LYRA) drops 15% this week, taking one-year losses to 49% (Simply Wall St.)
Nov-09-22 08:00AM	Lyra Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -15.52%
Nov-08-22 05:45PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 06:11AM	Bullish insiders at Lyra Therapeutics, Inc. (NASDAQ:LYRA) loaded up on US$1.5m of stock earlier this year (Simply Wall St.)
Sep-13-22 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study (PR Newswire)
Sep-10-22 08:00AM	LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting (PR Newswire)
Sep-08-22 07:00AM	Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients (PR Newswire)
Sep-06-22 07:00AM	Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022 (PR Newswire)
Aug-31-22 02:08PM	We're Hopeful That Lyra Therapeutics (NASDAQ:LYRA) Will Use Its Cash Wisely (Simply Wall St.)
Aug-29-22 07:00AM	Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR210 in Two Oral Presentations at ARS Annual Meeting (PR Newswire) +8.52%
Aug-11-22 08:05AM	Are Institutions Heavily Invested In Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) Shares? (Simply Wall St.)
Aug-09-22 08:25AM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-22 09:40AM	Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-22 09:21AM	Increasing losses over year doesn't faze investors as stock rallies 12% this past week (Simply Wall St.)
Jul-05-22 07:00AM	Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022 (PR Newswire)
07:00AM	Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer (PR Newswire)
Jun-17-22 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-26-22 07:00AM	Lyra Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palasis Maria	Officer	Oct 14 '25	Proposed Sale	7.23	537	3,881		Oct 14 03:09 PM
Palasis Maria	President & CEO	Jul 10 '25	Sale	8.91	1,565	13,944	1,098,435	Jul 14 09:27 PM
Cavalier Jason	Chief Financial Officer	Jul 10 '25	Sale	8.91	684	6,094	519,316	Jul 14 09:27 PM
Palasis Maria	Officer	Jul 10 '25	Proposed Sale	8.91	1,565	13,945		Jul 10 04:05 PM
Waksal Harlan	Officer	Apr 25 '25	Proposed Sale	0.10	145,370	14,930		Apr 25 03:41 PM
Palasis Maria	Officer	Apr 09 '25	Proposed Sale	0.09	39,567	3,545		Apr 09 03:44 PM

BBNX

Beta Bionics Inc

LYRA

Lyra Therapeutics Inc

Upgrade your FINVIZ experience